Two isoteric/isoelectronic dopamine analogs based of (2'-aminoethyl)-1-hydroxy-2-pyridone without having the COMT vulnerable m-hydroxy group were synthesized via ten synthetic steps. Their dopaminergic activities were evaluated by measuring the inhibitory effects of prolactin secretion from the anterior pituitary in rats. The compounds 1 and 2 caused a reduction of prolactin secretion at the 10(-6) M concentration. Semiempirical MO calculations (at the AM-1 level) were performed on 1 and 2 in order to understand the structural and electronic features as compared to dopamine.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A pilot exploratory study for analysis of clinical features and plasma catecholamines in blepharospasm.
Sci Rep
January 2025
Department of Neurology, The First Hospital of Jilin University, Changchun, China.
Blepharospasm (BSP) is a common focal movement disorder linked to the basal ganglia and plasma catecholamines (CAs). This study aimed to analyze clinical characteristics of BSP patients and explore the relationship with plasma CAs. Clinical characteristics, clinician-rated scales, and plasma CAs were recorded, including dopamine (DA), 3-methoxytyramine (3-MT), and the 3-MT/DA ratio.
View Article and Find Full Text PDFAbsolute measurement of fast and slow neuronal signals with fluorescence lifetime photometry at high temporal resolution.
bioRxiv
January 2025
Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, Boston MA 02115.
The concentrations of extracellular and intracellular signaling molecules, such as dopamine and cAMP, change over both fast and slow timescales and impact downstream pathways in a cell-type specific manner. Fluorescence sensors currently used to monitor such signals are typically optimized to detect fast, relative changes in concentration of the target molecule. They are less well suited to detect slowly-changing signals and rarely provide absolute measurements of either fast and slow signaling components.
View Article and Find Full Text PDFPreemptive hydromorphone analgesia reduces postoperative delirium and stress response in laparoscopic cholecystectomy patients.
Am J Transl Res
December 2024
Department of Anesthesiology, Xi'an Central Hospital No. 161, Xiwu Road, Xincheng District, Xi'an 710003, Shaanxi, China.
Objective: To evaluate the effects of preemptive hydromorphone analgesia on postoperative delirium and stress response in patients undergoing laparoscopic cholecystectomy.
Methods: A retrospective cohort study was conducted, including 167 patients who underwent laparoscopic cholecystectomy at Xi'an Central Hospital between June 2021 and November 2023. Patients were categorized into an observation group (n=87) receiving preemptive hydromorphone hydrochloride analgesia and a control group (n=80) without preemptive analgesia.
Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder.
Curr Neuropharmacol
January 2025
Clinic Villa Von Siebenthal, Rome, Italy.
Introduction/objective: Schizophrenia with substance use disorder is a complex clinical condition that may increase treatment resistance. Cannabis use disorder is frequently associated with psychosis and the causal link has still to be defined. Partial D2/3 agonists may ensure limbic dopamine release normalization while avoiding reduced frontocortical dopamine release, which would contribute to negative symptoms.
View Article and Find Full Text PDFPatent review of novel compounds targeting opioid use disorder (2018-2024).
Expert Opin Ther Pat
January 2025
Department of Pharmaceutical and Biomedical Sciences, Rudolph H. Raabe College of Pharmacy, Ohio Northern University, Ada, OH, USA.
Introduction: Opioids have served as a cornerstone in pain management for decades. However, the emergence of increasingly potent synthetic analogs brings forth a range of side effects, including respiratory depression, tolerance, dependence, constipation, and, more importantly, the development of severe and debilitating opioid use disorder (OUD). Search for therapeutics to mitigate OUD has been challenging and this has called for novel approaches that include design of small molecules targeting neuronal circuits involved in addiction (opioid, dopamine, serotonin, norepinephrine, and glutamate receptors, etc.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!